The international chronic myelomonocytic leukemia (CMML) treatment market is experiencing a period of significant growth. This expansion can be attributed to several factors, like the growing incidence of CMML, advancements in therapy, and growing awareness about the disease. The market is marked by a diverse portfolio of medicines available, inclu